VIA Investors Have Opportunity to Lead Via Transportation, Inc. Securities Lawsuit Share Post Post navigation Previous PostCureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global CommercializationNext Post LCID Deadline: LCID Investors with Losses in Excess of $100K Have Opportunity to Lead Lucid Group, Inc. Securities Fraud Lawsuit